论文部分内容阅读
在超临界二氧化碳分散体系中,借助于纳米尺寸为20nm的羟基磷灰石(HAP)中羟基的弱酸性,与聚4-乙烯基吡啶[P(4-VP)]中吡啶的弱碱性之间的弱酸碱作用,以偶氮二异丁腈(AIBN)为引发剂,诱导4-VP进行自由基聚合,制得了P(4-VP)/HAP纳米复合材料。考察了不同HAP含量、交联剂配比、不同反应温度、反应压力对产物形貌、产率的影响。最优制备方案为:0.100g AIBN,0.500g MBA,反应压力为19MPa,反应温度80℃,反应8h,产物粒径约1μm;溶胀率在pH=2~3时较高,SR=2.97。初步研究了P(4-VP)/HAP纳米复合材料对药物的缓释性能,通过调整环境pH值控制药物的缓释性能,pH=1.4时,在1h内药物释放基本完毕;在pH=7.8时,药物释放约3h,同时HAP聚合后的复合物的机械性能也得到了增强。
In the supercritical carbon dioxide dispersion, the weakly acidic hydroxyl group of hydroxyapatite (HAP) with a size of 20 nm and the weakly basic nature of the pyridine in the poly 4-vinyl pyridine [P (4-VP)] P (4-VP) / HAP nanocomposites were prepared by free radical polymerization of 4-VP with azobisisobutyronitrile (AIBN) as initiator. The effects of different HAP content, cross-linking agent ratio, different reaction temperature and reaction pressure on the morphology and yield of the product were investigated. The optimum preparation scheme is as follows: 0.100g AIBN, 0.500g MBA, reaction pressure 19MPa, reaction temperature 80 ℃, reaction time 8h, the product particle size is about 1μm; swelling rate is higher at pH = 2-3, SR = 2.97. The drug release properties of P (4-VP) / HAP nanocomposites were studied preliminarily. The drug release was controlled within 1h by adjusting the pH value of the environment. At pH = 7.8 , The drug was released for about 3 h and the mechanical properties of the HAP-polymerized complex were also enhanced.